The Peptide Field. Cerebrolysin: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/cerebrolysin

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=cerebrolysin#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: Authorized in Austria; no FDA-approved Cerebrolysin product was identified in the United States as reviewed August 30, 2026

Exact product limits: Cerebrolysin is a specific finished product made from a pig-brain-derived peptide mixture. An FDA substance record and an Austrian authorization do not make every brain hydrolysate, compounded product, or online product equivalent to Cerebrolysin.

Human outcomes: Moderate. Randomized human studies include a large stroke trial and smaller dementia trials. The largest stroke trial found no significant difference on its main recovery measure.

Body effects in people: Limited. Cerebrolysin is a mixture, not one defined molecule. Its product information says researchers cannot directly track the whole mixture through the body.

What the evidence shows: CASTA was the largest randomized stroke trial. It enrolled 1,070 adults with a stroke caused by a blocked blood vessel. Its main recovery measure found no clear difference between Cerebrolysin and placebo. A 2023 Cochrane review covered seven studies and 1,773 people. It included one study of Cortexin, a similar product. The review found no clear drop in deaths. It found a possible rise in serious health problems that did not cause death.

What remains unknown: A 2019 Cochrane review covered six vascular-dementia studies with 597 people. Study problems made the evidence very uncertain. Any benefit might be too small to matter. One Alzheimer's study included 192 people, but it did not settle the wider question. FDA has an identity record and an orphan drug designation for Cerebrolysin. Neither means product approval. No FDA-approved U.S. product was found. Online and related brain-peptide products are not proven equal to Cerebrolysin.

Safety limits: The available evidence does not define the full safety profile of every Cerebrolysin product or related mixture. The 2023 stroke review found a possible increase in serious health problems that did not cause death. This guide does not diagnose, treat, recommend, or provide product-use or sourcing instructions.

Approval claim: “Cerebrolysin is FDA-approved in the United States.”
Verdict: Misleading. No FDA-approved U.S. Cerebrolysin product was identified in the reviewed approval database. An FDA substance record or orphan designation does not mean that FDA approved a product.
Evidence basis: Regulatory or product record. Scope: United States regulatory status as reviewed August 30, 2026. Austrian authorization is a separate country status.
Claim sources: https://precision.fda.gov/ginas/app/ui/substances/8880c9ea-4705-45eb-b514-40316e135bdd https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. FDA Global Substance Registration System record for Cerebrolysin. 2026. Accessed 2026-08-30. https://precision.fda.gov/ginas/app/ui/substances/8880c9ea-4705-45eb-b514-40316e135bdd

U.S. Food and Drug Administration. FDA orphan drug designation explainer. 2026. Accessed 2026-08-30. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products

U.S. Food and Drug Administration. FDA drug approvals and databases. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

Austrian Federal Office for Safety in Health Care (BASG). Cerebrolysin Austrian product information. 2021. Accessed 2026-08-30. https://medikamente.basg.gv.at/documents/1-21380__DOTC_FACH_INFO.pdf

PubMed · Stroke. CASTA randomized acute stroke trial. 2012. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/22282884/

ClinicalTrials.gov. CASTA trial record (NCT00868283). 2009. Accessed 2026-08-30. https://clinicaltrials.gov/study/NCT00868283

PubMed · Cochrane Database of Systematic Reviews. Cochrane review of Cerebrolysin for acute ischemic stroke. 2023. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/37818733/

PubMed · Cochrane Database of Systematic Reviews. Cochrane review of Cerebrolysin for vascular dementia. 2019. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/31710397/

PubMed · Journal of Neural Transmission. Randomized Cerebrolysin study in Alzheimer's disease. 2002. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/12111446/

PubMed · Drug Testing and Analysis. Peptide profile of an Internet-obtained Cerebrolysin sample. 2015. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/26017115/

PubMed · Journal of Medical Life. Comparison of Cerebrolysin with other peptide preparations. 2024. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/38737662/

World Anti-Doping Agency. 2026 Prohibited List. 2026. Accessed 2026-08-30. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

Keep the limits, review date, and sources with this record. Check the current source for changes.